Wall Street analyst estimates for Zimmer Biomet Holdings, Inc. (ZBH): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 17 |
| Hold | 22 |
| Sell | 3 |
| Strong Sell | 0 |
| Total analysts | 42 |
| Avg rating (1-5) | 0.33 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $1.88 | ||
| 2026-08-05 | $2.07 | $2.01 | +3.0% |
| 2026-04-28 | $2.09 | $1.86 | +12.4% |
| 2026-02-10 | $2.42 | $2.38 | +1.7% |
| 2025-11-05 | $1.90 | $1.87 | +1.6% |
| 2025-08-07 | $2.07 | $1.98 | +4.5% |
| 2025-05-05 | $1.81 | $1.77 | +2.3% |
| 2025-02-06 | $2.31 | $2.30 | +0.4% |
Valuation Ratios
| P/E Ratio | 21.48 |
| Price / Book | 1.34 |
| EV / EBITDA | 12.33 |
| Dividend Yield | 1.09% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.67B | $7.80B | $7.93B | $7.98B | $6.13B | $6.83B | $6.94B | $7.39B | $7.68B | $8.23B |
| Cost of Revenue | $2.38B | $2.13B | $2.27B | $2.25B | $1.82B | $1.96B | $2.02B | $2.08B | $2.19B | $3.16B |
| Gross Profit | $5.29B | $5.67B | $5.66B | $5.73B | $4.30B | $4.87B | $4.92B | $5.31B | $5.49B | $5.07B |
| Research & Development | $365.6M | $369.9M | $391.7M | $449.3M | $322.8M | $435.8M | $406.0M | $458.7M | $437.4M | $458.5M |
| Selling, General & Admin | $2.94B | $3.10B | $3.38B | $3.34B | $2.71B | $2.84B | $2.76B | $2.84B | $2.93B | $3.25B |
| Operating Expenses | $4.47B | $4.87B | $5.63B | $4.59B | $4.22B | $4.01B | $4.22B | $4.03B | $4.20B | $3.71B |
| Operating Income | $821.1M | $799.3M | $33.8M | $1.14B | $83.1M | $860.3M | $696.3M | $1.28B | $1.29B | $1.36B |
| EBITDA | $1.79B | $1.85B | $1.06B | $2.14B | $1.01B | $1.65B | $1.49B | $2.22B | $2.25B | $2.22B |
| Interest Expense | $355.0M | $325.3M | $289.3M | $226.9M | $212.1M | $208.4M | $164.8M | $201.2M | $218.0M | $292.8M |
| Pre-tax Income | $399.6M | $464.6M | -$271.1M | $905.8M | -$105.2M | $499.0M | $403.5M | $1.07B | $1.04B | $830.8M |
| Income Tax | $95.0M | -$1.35B | $108.2M | -$225.7M | -$96.0M | $53.5M | $112.3M | $42.2M | $131.4M | $125.7M |
| Net Income | $305.9M | $1.81B | -$379.2M | $1.13B | -$138.9M | $401.6M | $231.4M | $1.02B | $903.8M | $705.2M |
| EPS | $1.51 | $9.11 | $-1.86 | $5.52 | $-0.67 | $1.93 | $1.10 | $4.91 | $4.45 | $3.56 |
| EPS (Diluted) | $1.50 | $9.03 | $-1.86 | $5.47 | $-0.67 | $1.91 | $1.10 | $4.88 | $4.43 | $3.55 |
| Shares Outstanding (Diluted) | $202.4M | $203.7M | $203.5M | $206.7M | $207.0M | $210.4M | $210.3M | $209.7M | $203.9M | $198.7M |
Price
| Price | $88.29 |
| Market Cap | $17.1B |
| Exchange | NYSE |
| Country | US |
Related companies: DGX · DXCM · ILMN · INCY · LH · SNN · STE
Explore sector: Healthcare · Medical - Devices
More sections of ZBH: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks